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Jarno Gauffin1*†, Tiina Hankama2†, Hannu Kautiainen3,4, Pekka Hannonen2,5 and Maija Haanpää6,7Abstract
Backround: Fibromyalgia has a plethorae of symptoms, which can be confusing and even misleading. Accurate
evaluation is necessary when patients with fibromyalgia are treated. Different types of instruments are available for
the clinicians to supplement evaluation. Our objective was to study the applicability of the PainDETECT instrument
to screen neuropathic pain in patients with fibromyalgia.
Methods: 158 patients with primary fibromyalgia underwent a neurological examination including bedside sensory
testing. They also fulfilled four questionnaires: PainDETECT, Beck depression inventory IA (BDI IA), Fibromyalgia
Impact Questionnaire (FIQ) and a self-made questionnaire regarding present pain and pain relieving methods of
the patients. The results of the clinical evaluation and questionnaires were then compared.
Results: Clinically verified neuropathic pain was diagnosed in 53/158 [34% (95% Cl: 26 to 41)] patients. The ROC
curve achieved a maximum Youden´s index at score of 17 when sensitivity was 0.79 (95% Cl: 0.66 to 0.89) and
specificity 0.53 (95% Cl: 0.43 to 0.63). The PainDETECT total score (OR: 1.14 95% Cl: 1.06 to 1.22), FM as the worst
current pain (OR: 0.31; 95% 0.16 to 0.62), body mass index (BMI) (OR: 1.05; 95% Cl: 1.00 to 1.11) and the intensity of
current pain (OR: 1.20; 95% Cl: 1.01 to 1.41) were significantly associated with the presence of neuropathic pain in
univariate analyses.
Conclusion: This study highlights the importance of thorough clinical examination. The Neuropathic pain screening
tool PainDETECT is not as useful in patients with fibromyalgia as in patients with uncompromised central pain
control.Background
Fibromyalgia (FM) is a chronic pain syndrome, which affects
up to 5% of the general population [1]. Characteristic
features of FM are widespread musculoskeletal pain and ten-
derness as well as fatigue in the absence of any explanatory
organic disease [2]. Other usual symptoms are disturbed
sleep, cognitive problems and a variety of psychosomatic
symptoms originating from various organs [3]. Patients with
FM often complain also about tingling, numbness, burning
pain, cutaneous hyperalgesia, and pain attacks [4], which are
typical symptoms of neuropathic pain. The IASP (Inter-
national Association for Study of Pain) defined neuropathic
pain recently as “pain caused by a lesion or disease of the
somatosensory system” [5]. The prevalence of neuropathic
pain in the general population is poorly known. Two* Correspondence: jarno.gauffin@orton.fi
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reproduction in any medium, provided the orpopulation-based studies from Europe reported the preva-
lence of pain predominantly of neuropathic origin [6] or pain
with neuropathic characteristics [7] to be 8% and 7%, re-
spectively when assessed with a screening questionnaire
without clinical confirmation of the diagnosis. According
to a population-based study, the prevalence of neuro-
pathic pain is around 10% in citizens aged 30 years or
older [8].
Neuropathic pain screening tools such as PainDETECT
are recommended for identifying patients with suspected
neuropathic pain, particularly when used by non-specialists
[9,10]. Baron et al. [11] also showed that PainDETECT is
useful for identifying different sensory profiles of neuro-
pathic pain when a neuropathic pain condition (e.g. dia-
betic neuropathy or postherpetic neuralgia) has already
been diagnosed. PainDETECT, which was developed and
validated in Germany, incorporates a self-report question-
naire with 9 items [12]. There are 7 weighted sensory de-
scriptor items and 2 items relating to the spatial (radiating)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Its sensitivity and specificity compared to clinical diagnosis
is 85% and 80%, respectively. PainDETECT was initially
developed and validated in patients with back pain but has
shown applicability also to patients with other types of
neuropatic pain. When using PainDETECT for screening
purposes Freynhagen et al. [12] found cut-off scores ≤
12 (a neuropathic component is unlikely) and ≥ 19 (a neuro-
pathic component is likely) to be most appropriate.
PainDETECT has been translated into several languages,
including Finnish.
In this study we report the applicability of the
PainDETECT tool to screen neuropathic pain in patients
with fibromyalgia (FM).
Methods
Patients
Participants for the study were recruited from the
patients with FM who had been diagnosed and treated
in outpatient departments of Rheumatology or Physical
medicine and rehabilitation of Jyväskylä Central Hospital
between 2006 and 2008. Patients were identified using
the ICD-10 code M79.0 according to the 2006 version.
Based on medical records, patients with previously
diagnosed neuropathic pain or neuropathy, active in-
flammatory arthritis, systemic connective tissue disease,
cognitive impairment, severe psychiatric disorders
(e.g., psychotic disorder, major depression, or severe
anxiety disorder diagnosed by a psychiatrist) or any
other unstable disease (e.g., cancer) were excluded.
Only patients aged 18–65 years were included.
Data collection
The questionnaires and consent form were sent to all
traceable patients. The patients were asked to fill in four
questionnaires: (1) PainDETECT [12], (2) Beck depres-
sion inventory IA (BDI IA) [13], (3) Fibromyalgia Impact
Questionnaire (FIQ) [14], and (4) a one-page self-made
questionnaire. Beck depression inventory IA is a 21-item
questionnaire to assess possible depression and it is
validated in Finnish [15]. FIQ is a multidimensional self-
administered questionnaire including 10 questions, which
evaluate physical functioning, work status, depression,
anxiety, sleep, pain, stiffness, fatigue and well-being. It is
also validated in Finnish [16]. The self-made questionnaire
included questions regarding the pain condition of the
patients, the intensity of their current pain, the effect of
their pain relief methods, and the rank of FM pain
compared to other possible pains.
Those who replied were invited to a clinical visit,
where an experienced physician (TH) examined the
patients and confirmed the diagnosis of FM according to
the criteria of the American College of Rheumatology
[17]. Based on careful clinical history and physicalexamination, including neurological examination with
meticulous bedside sensory testing, she also assessed
whether the patient had neuropathic pain or not [18].
The level of certainty of the neuropathic pain diagnosis
was graded as definite, probable or possible [19]. The
grading system has four items: 1. Pain with a distinct
neuroanatomically plausible distribution. 2. History sug-
gestive of a relevant lesion or disease affecting the periph-
eral or central somatosensory system. 3. Demonstration of
the distinct neuroanatomically plausible distribution by at
least one test. And 4. Demonstration of the relevant lesion
or disease by at least one test. The definite grade requires
all items 1. to 4. The probable grade requires items 1. and
2. plus either 3. or 4. The possible grade requires items 1.
and 2.
Statistical methods
Results were expressed as means with standard deviation
(SD) and 95% confidence intervals (CIs), and as medians
with interquartile range (IQR). Statistical comparison be-
tween the groups was performed by t-test, permutation
test or Chi-square test, when appropriate. Relationships
between neuropathic pain and important risk factors
were analyzed with univariate and multivariate forward
stepwise logistic regression models. Receiver operating
characteristic (ROC) curve was constructed to determine
the cut-off point of PainDETECT that corresponds to
the clinically verified neuropathic pain, with bias
corrected bootstrap CIs. Values for the area under the
ROC curve from 0.7 to 0.8 indicate reasonable discrim-
ination and values exceeding 0.8 indicate good discrim-
ination. We defined the best cut-off value as the value
with the highest accuracy that maximizes the Youden's
index. Sensitivity, specificity, positive predictive value,
likelihood ratio, Youden's index, and their 95% CI values
were calculated.
Ethical aspects
The study protocol was approved by The Committee of
Research Ethics of Central Finland Health Care District,
and the patients gave their informed consent in writing.
Results
The postal survey was mailed to 239 patients with pri-
mary FM, and 169 patients (71%) replied. Five patients
declined to attend the clinical visit due to long distances.
Six patients had filled in questionnaires insufficiently
and were excluded from the analyses. Hence 158
patients who had undergone clinical evaluation and had
completed the questionnaires adequately were included
in the analyses. All of them fulfilled the diagnostic cri-
teria of primary FM. In addition to FM, clinically verified
neuropathic pain was diagnosed in 53/158 [34% (95% Cl:
26 to 41)] patients. Neuropathic pain was definite in 16
Table 1 Demographic and clinical data of 158 FM
patients with and without neuropathic pain diagnosis
Variables NP
N = 53
NNP
N = 105
P-value
Females, number (%) 49 (92) 100 (95) 0.48
Age, mean (SD) 49 (8) 46 (12) 0.074
BMI, mean (SD) 29.6 (6.6) 27.3 (6.6) 0.041
Duration of diagnosis, median (IQR) 4 (2.7) 3 (2.8) 0.53
FIQ, mean (SD) 52.3 (19.4) 48.0 (20.1) 0.19
PainDETECT score, mean (SD) 19.8 (5.0) 15.9 (5.8) <0.001
Beck Depression Inventory,
mean (SD)
14.4 (7.2) 13.5 (9.4) 0.57
Efficacy of pain relief*, mean (SD) 6.3 (1.7) 6.8 (1.8) 0.13
Health score**, mean (SD) 5.8 (2.1) 5.8 (2.0) 0.95
Current pain intensity***, mean (SD) 6.3 (2.0) 5.6 (2.2) 0.033
Number of patients with FM pain as
their worst current pain (%)
22 (41) 73 (70) <0.001
NP = neuropathic pain, NNP = non-neuropathic pain, BMI = body mass index,
FIQ = Fibromyalgia Impact Questionnaire.
*Expressed as numerical rating scale (0 = no pain relief, 10 =maximal
pain relief).
** Expressed as numerical rating scale (0 = poor health, 10 =maximal state
of health).
*** Expressed as numerical rating scale (0 = no pain, 10 = worst
imaginable pain).
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sible in 7 (4%) patients. The PainDETECT score and the
intensity of current pain were significantly higher in the
patients with neuropathic pain compared to those with-
out it. FM pain was regarded as the worst current pain
in 70% of the patients without neuropathic pain and in
41% of the patients with neuropathic pain (p < 0.001)
(Table 1, Figure 1). The neuropathic pain diagnoses ofPain DE
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Figure 1 Distribution of the PainDETECT scores according to the presthe 46 patients with definite or probable neuropathic
pain are listed in Table 2.
The ROC curve achieved a maximum Youden´s index
at score of 17 when sensitivity was 0.79 (95% Cl: 0.66 to
0.89) and specificity 0.53 (95% Cl: 0.43 to 0.63). The area
under the curve was 0.69 (95% Cl: 0.60 to 0.77). The
predictive value of a positive test and likelihood ratio
(positive) were 0.46 (95% Cl: 0.36 to 0.57) and 1.7 (95%
Cl: 1.33 to 2.17) respectively (Table 3, Figure 2).
The PainDETECT total score (OR: 1.14 95% Cl: 1.06
to 1.22), FM as the worst current pain (OR: 0.31; 95%
0.16 to 0.62), body mass index (BMI) (OR: 1.05; 95% Cl:
1.00 to 1.11) and the intensity of current pain (OR: 1.20;
95% Cl: 1.01 to 1.41) were significantly associated with
the presence of neuropathic pain in univariate analyses.
The PainDETECT score and the patient’s own assess-
ment of FM pain as their worst pain entered into the
forward logistic regression model (Table 4).
Discussion
Our main finding showed that PainDETECT cannot dis-
tinguish neuropathic pain from non-neuropathic pain in
FM patients. In the PainDETECT validation study a cut-
off value of 19 points had both sensitivity and specificity
of 0.84 [12], whereas that cut-off value reached sensitiv-
ity of 0.59 and specificity of 0.67 in our cohort. In our
study the optimal cut-off value was 17 points with sensitiv-
ity of 0.79 and a low specificity of 0.53. The PainDETECT
score and FM as the worst current pain had the strongest
association with the presence of neuropathic pain, the lat-
ter having negative association, i.e., FM pain as the worst
current pain proved to be a protective marker to neuro-
pathic pain. Based on these results of sensitivity and speci-
ficity we do not recommend the use of PainDETECT forTECT Score
20 25 30 35
ence or absence of neuropathic pain diagnosis in FM patients.
Table 2 Neuropathic pain diagnoses in 46 patients with
probable or definite neuropathic pain
NP diagnoses Probable
NP N = 30
Definite
NP N = 16
Method(s) of
confirming
definite NP
diagnosis
Lumbar radiculopathy 20 8 ENMG (4),
lumbar MRI (4)
Thoracic radiculopathy 1
Cervical radiculopathy 2 1 cervical MRI
Painful polyneuropathy 0 2 ENMG (2),
gene test* (1)
Peripheral nerve
entrapment #
4 3 ENMG
Peripheral nerve
lesion ¤
3 2 ENMG
NP = neuropathic pain.
* confirming the diagnosis of hereditary polyneuropathy.
# compression of median nerve in 3 and ulnar nerve in 2, tarsal tunnel
syndrome in 1.
¤ lesion of peroneal nerve 2, ulnar nerve in 1, cervical plexus in 1 and
trigeminal nerve in 1.
False-Positivity Probability (1-Specificity)
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AUC = 0.69 (95% CI: 0.60 to 0.77)
Optimal cut-off value = 17
Sensitivity = 0.79 (95% CI: 0.66 to 0.89)
Specificity = 0.53 (95% CI: 0.43 to 0.63)
Figure 2 ROC curve of PainDETECT scores when used to define
the presence of neuropathic pain.
Table 4 Logistic regression models for the odds to
presence of neuropathic pain in FM patients
Variable Univariate
OR (95% CI)
P value Multivariate*
OR (95% CI)
P value
Female gender 0.61 (0.16
to 2.38)
0.48
Age 1.03 (1.00
to 1.07)
0.076
Body mass index 1.05 (1.00
to 1.11)
0.048
Duration of
fibromyalgia
diagnosis
1.02 (.96
to 1.08)
0.59
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worth noting that FM patients were excluded from the val-
idation studies of PainDETECT [12] and DN4 (another
neuropathic pain screening tool) [20]. Likewise patients
with “mixed pain” were excluded from the validation study
of LANSS [21]. A recent review recommended that neuro-
pathic pain screening tools should not be used for patients
with widespread pain [22]. Although neuropathic pain
screening tools have not been validated with FM patients,
Rhem et al. [4] and Koroschetz et al. [23] used PainDETECT
to classify FM patients on the basis of their sensory
symptoms. On the basis of LANSS results in FM patients
Martinez-Lavin et al. [24] even suggested that FM might be
a neuropathic pain state.
Although patients with previously diagnosed neuro-
pathic pain were excluded, and therefore the prevalenceTable 3 Characteristics with 95 per cent confidence
intervals of performance of different PainDETECT cut-off
scores
Characteristics PainDETECT screening
Cut-off score
12 17 19
Sensitivity 0.94 (0.84
to 0.99)
0.79 (0.43
to 0.89)
0.58 (0.44
to 0.72)
Specificity 0.29 (0.20
to 0.38)
0.53 (0.43
to 0.63)
0.67 (0.57
to 0.76)
Predictive value of
positive test
0.40 (0.31
to 0.49)
0.46 (0.36
to 0.57)
0.47 (0.35
to 0.60
Likelihood ratio (positive) 1.32 (1.14
to 1.53)
1.70 (1.33
to 2.17)
1.75 (1.23
to 2.50)
Youden's index 0.23 (0.13
to 0.33)
0.33 (0.17
to 0.47)
0.25 (0.08
to 0.41)
FIQ 1.12 (.94
to 1.33)
0.19
PainDETECT total
score
1.14 (1.06
to 1.22)
<0.001 1.16 (1.08
to 1.25)
<0.001
Beck Depression
Inventory
1.01 (.97
to 1.05)
0.56
Efficacy of pain
relief
0.86 (.71
to 1.04)
0.12
Health score 0.99 (.84
to 1.17)
0.92
Current pain
intensity
1.20 (1.01
to 1.41)
0.034
FM pain as the
worst current
pain
0.31 (.16
to .62)
<0.001 0.25 (0.11
to 0.53)
<0.001
IPAQ 1.00 (1.00
to 1.00)
0.56
*Forward selection. Only those variables are shown which entered the model.
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neuropathic pain was found in 37% of the patients. This
is about five-fold compared to the prevalence in the gen-
eral population according to the studies using LANSS
[6] and DN4 [7].
It is important to bear the possibility of neuropathic pain
in mind when a FM patient complains of sensory
symptoms and pain with neuroanatomically plausible dis-
tribution. In such cases, careful examination of the patient
is needed to support or exclude the diagnosis of neuro-
pathic pain; FM and neuropathic pain are not mutually
exclusive. Depending of the location of the pain and
findings in the bedside examination, additional test (e.g.,
electroneuromyography in suspected peripheral nerve
lesion, quantitative sensory testing and skin biopsy in
suspected small fiber neuropathy, or magnetic resonance
imaging in suspected central nervous system lesion) may
be indicated (see more detailed report in [10,18]).
It is generally assumed that the bodily distress disorders
are highly associated with emotional distress, e.g., mood
disorder. However, according to the BDI results, our
patients with and without neuropathic pain had similar
level of depressive symptoms.
The limitations of our study are retrospective setting,
cross-sectional clinical evaluation, descriptive nature of the
study (we were not allowed to perform additional diagnos-
tic procedures to improve the level of certainty of the
neuropathic pain diagnosis), secondary health care setting,
and ignorance of other pains but FM and neuropathic pain.
Diagnosis of neuropathic pain may give an opportunity
for curative treatment of the cause of neuropathic pain
(e.g., surgical release of a nerve entrapment). In addition,
patients with both FM and neuropathic pain might be
favorable candidates for a treatment trial with tricyclic
antidepressants, pregabalin or duloxetine, which have
proved their efficacy for both conditions [25-27].
Conclusion
This study highlights the importance of thorough clinical
examination when a FM patient emerges with new
symptoms. Neuropathic pain screening tools such as
PainDETECT are not as useful for FM patients as for other
patient. However, if it is used, a positive PainDETECT score
still attracts the clinician’s attention to the possibility of
neuropathic pain and encourages performing an adequate
neurological examination and the consideration of further
testing when needed.
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